Konstantinos Tellis, PhD



Teaching Staff in Laboratory of Biochemistry & Clinical Chemistry, Department of Chemistry, University of Ioannina, 45110, Greece

Partner of the Atherothrombosis Research Centre (ARC) of the University of Ioannina, Greece

Tel: 2651008326, 6973381582 E-mail: ktellis@uoi.gr

Title: Doctor in Biochemistry and Clinical Chemistry.

Education: a) Diploma of Chemistry, School of Sciences, University of Ioannina (U.O.I.) (1993). b) Doctoral Degree in Biochemistry of lipids and membranes, Department of Chemistry, U.O.I., Greece (1999).

Postdoctoral research fellowships: a) Laboratory of Biological Chemistry, School of Medicine, U.O.I. b) Laboratory of Biochemistry and Clinical Chemistry, Department of Chemistry.

Scientifc Interests.: Biochemistry, clinical chemistry, lipids, lipoproteins, pathophysiology of atherosclerosis and atherothrombosis. The role of platelets, oxidized lipoproteins and inflammation in the development, progression of atherosclerotic plaque, biochemical characteristics and biological activities of the native or oxidized forms of the lipoprotein in patients with various types of dyslipidemias, cardiovascular disease and chronic kidney disease.

Participation in Research Projects: 8.

Member of scientific societies: a)European Atherosclerosis Society (EAS), b) Hellenic Atherosclerosis Society (HES), c) Greek Society of Free Radicals and Oxidative Stress, d) Hellenic Union of Chemists e) Hellenic Society of Biochemistry and Molecular Biology. <u>Committee members</u>: a) Greek Society of Free Radicals and Oxidative Stress, b) Association of Greek Chemists c) Pathophysiology of Atherosclerosis Hellenic Society of Atherosclerosis.

Reviewer in scientific Journals: Analytical chemistry, Expert Opinion On Therapeutic Patents, Cardiovascular Diabetology, BMC Cardiovascular Disorders, Hellenic Journal of Atherosclerosis, Lipids in Health and Disease. **Editorial Board Associated Editor**: Hellenic Journal of Atherosclerosis.

Note-Book(s): 6.

Abstracts in national and international Congresses: >150.

Publications: 63.

Metrics a) Scopus: <u>h-index</u>: **17**, <u>citation</u>: **953**, b) Google Scholar: <u>h-index</u>: **20**, <u>citation</u>: 1447, <u>i10-index</u>: 33. **Representative publications**:

1. Dafnis I, Tsouka A N, Gkolfinopoulou C, Tellis C C, Chroni A, Tselepis A D. PCSK9 is minimally associated with HDL but impairs the anti-atherosclerotic HDL effects on endothelial cell activation. *J Lipid Res*. 2022, 63(10):100272.

2. Pappas-Gogos G , Tepelenis K, Goussia A, Tellis C, Fousekis F, Glantzounis G K, Vlachos K. Plasma VEGF and Leptin Values in Patients With Gastric Intestinal Metaplasia and Metabolic Syndrome. *Front Oncol.* 2022, 31;12:905168

3. Dounousi E, Tellis C, Pavlakou P, Duni A, Liakopoulos V, Mark PB, Papagianni A, Tselepis AD. Association between PCSK9 Levels and Markers of Inflammation, Oxidative Stress, and Endothelial Dysfunction in a Population of Nondialysis Chronic Kidney Disease Patients. *Oxid Med Cell Longev*. 2021; 2020,21:6677012.

5 Tsouka AN, Tellis CC, Tselepis AD. Pharmacology of PCSK9 Inhibitors: Current Status and Future Perspectives. *Curr Pharm Des.* 2018;24(31):3622-3633.

6. Cinoku I, Mavragani CP, Tellis CC, Nezos A, Tselepis AD, Moutsopoulos HM. Autoantibodies to ox-LDL in Sjögren's syndrome: are they atheroprotective? *Clin Exp Rheumatol.* 2018;112(3):61-67.

7. Zvintzou E, Lhomme M, Chasapi S, Filou S, Theodoropoulos V, Xapapadaki E, Kontush A, Spyroulias G, Tellis CC, Tselepis AD, Constantinou C, Kypreos KE. Pleiotropic effects of apolipoprotein C3 on HDL functionality and adipose tissue metabolic activity. *J Lipid Res*. 2017;58(9):1869-1883.

8. Filippatos TD, Liberopoulos E, Georgoula M, Tellis CC, Tselepis AD, Elisaf M. Effects of increased body weight and short-term weight loss on serum PCSK9 levels - a prospective pilot study. *Arch Med Sci Atheroscler Dis.* 2017;2:e46-e51.